Israeli drug prevents 100% of COVID patients from deteriorating in trial
(Worthy News) – All 18 COVID-19 patients hospitalized with moderate or severe symptoms who received the drug Amor-18 developed by Israeli biotech company Amorphical recovered and were discharged in a few days, the company announced on Wednesday. Of the 19 individuals who were given a placebo, six had to be transferred to intensive care, and two died.
As part of compassionate care, two other patients in a very serious condition were given the drug. Both recovered and were discharged.
“Since the patients treated with the drug recovered within a few days and were released to their home, this was 100% successful,” said Dr. Nashat Abu Saleh, co-director of the coronavirus department at Ziv Medical Center in Safed, where the phase II clinical trial was conducted. [ Source: Jerusalem Post (Read More…) ]
Worthy News reports from a biblical worldview with a commitment to accuracy, transparency, and editorial independence. Learn more about About Worthy News, our Editorial Standards, AI Use Policy, Ownership of Worthy News, News Tips and Corrections, and Worthy News Staff.
💡 Did you know? One of the best ways you can support Worthy News is by simply leaving a comment and sharing this article.
📢 Social media algorithms push content further when there’s more engagement — so every 👍 like, 💬 comment, and 🔄 share helps more people discover the truth. 🙌